# Juvmo (tavapadon) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tavapadon

> The FDA approved Juvmo (tavapadon), sponsored by AbbVie Inc. (ABBV), on October 30, 2026 for with Parkinson's disease.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Juvmo (tavapadon) |
| Codes | PF-06649751, CVL-751 |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | with parkinson's disease, [parkinson's disease](https://sec-api.dev/indications/parkinson-s-disease), To treat Parkinson’s disease in adults, [Parkinson Disease](https://sec-api.dev/indications/parkinson-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-K (accession 0001551152-25-000020): "•In September 2024, AbbVie announced positive top-line results from its Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease." https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm

### Dec 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-K (accession 0001551152-25-000020): "•In December 2024, AbbVie announced positive top-line results from its pivotal Phase 3 TEMPO-2 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson's disease." https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm

### October 31, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: Parkinson's disease.
- First seen 2025-10-31, last confirmed 2025-10-31.
- Press release filed with the SEC (EX-99) (accession 0001551152-25-000047): "•AbbVie announced that it submitted a New Drug Application (NDA) to the FDA for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist for the treatment of Parkinson's disease (PD)." https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm

### December 1, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Parkinson Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04760769 (Open-label Trial in Parkinson's Disease (PD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-01 (ACTUAL); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04760769

### September 25, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat Parkinson’s disease in adults.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Juvmo | tavapadon | 9/25/2026 | To treat Parkinson’s disease in adults" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "NDA220415 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260925, review_priority STANDARD; sponsor_name ABBVIE; product JUVMO (TAVAPADON)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220415%22

### October 30, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with Parkinson's disease.
- First seen 2026-10-30, last confirmed 2026-10-30.
- Press release filed with the SEC (EX-99) (accession 0001551152-26-000033): "•AbbVie announced the FDA approved Juvmo (tavapadon) tablets as the only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease (PD)." https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm

## Same indication

- [Aci-7104.056 at dose a](https://sec-api.dev/pdufa/aci-7104-056-at) (ACIU)
- [ARV-102](https://sec-api.dev/pdufa/arv-102) (ARVN)
- [Bhv-8000 10mg](https://sec-api.dev/pdufa/bhv-8000) (BHVN)
- [Biib122 225 mg](https://sec-api.dev/pdufa/biib122) (BIIB)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Lenrispodun](https://sec-api.dev/pdufa/lenrispodun) (JNJ)
- [Low dose gt-02287](https://sec-api.dev/pdufa/low-dose-gt-02287) (GANX)
- [Rexaceract](https://sec-api.dev/pdufa/rexaceract) (GANX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tavapadon.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Juvmo (tavapadon) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tavapadon

```bibtex
@misc{secapidev_pdufa_tavapadon_20261116,
  title        = {Juvmo (tavapadon) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tavapadon}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tavapadon_20261116","title":"Juvmo (tavapadon) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tavapadon","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
